Table 1 Candidate unmet clinical needs (UCNs)

1

Providing evidence of the benefits and risks of DOACs in MPNs

2

Providing evidence of the optimal duration of anticoagulant therapy in patients with MPN and thrombosis

3

Increasing the evidence on efficacy of ruxolitinib as antithrombotic agents

4

Improving knowledge of the association between driver mutations and risk factors for thrombosis in MPNs

5

Testing the validity of surrogate endpoint for the experimental assessment of antithrombotic action of cytoreductive drugs in MPNs

6

Providing evidence of the benefits and risks of cytoreduction in patients with SVT thrombosis without hypercythemia

7

Providing evidence of the benefits and risks of JAK2 inhibitors in MPN-associated SVT

8

Improving knowledge on risk factors of recurrence of thrombosis in MPNs

9

Improving knowledge of the role acquired thrombophilia has on the development of thrombosis in MPNs

10

Improving knowledge of the time from an MPN-associated thrombotic event and diagnosis of MPN

11

Improving knowledge of the role of mutated endothelium in the pathogenesis of thrombosis in MPNs

12

Improving knowledge of the leukocyte number as a risk factor for thrombosis and bleeding in MPNs

13

Improving the diagnostic pathway of MPNs in the setting of splanchnic vein thrombosis

14

Improving the diagnostic pathway of MPNs in the setting of cerebral vein thrombosis

15

Optimizing the use of Willebrand test for assessing the risk of bleeding in extreme thrombocytosis in MPNs

16

Improving the use of primary antithrombotic prophylaxis in patients with myelofibrosis

17

Improving the dosing regiments of aspirin in ET

18

Improving antithrombotic prophylaxis in MPN pregnant patients